Ulrik Kihlbom
Ulrik Kihlbom
Associate Professor of Medical Ethics
Senior Lecturer in Medical Ethics
Ulrik Kihlbom is is associate professor and senior lecturer in medical ethics at the Centre for Research Ethics & Bioethics. He works mainly on bioethical issues related to patients’ perspective and decision-making, methodology and ethical particularism. He is currently work package lead in the three year project MEET-AML, as well as in the five-year project looking at how and when to include patient preferences in the life cycle of medical products (PREFER). He lectures at various courses at the Medical school as well as for an advanced level course on public health ethics. He is also member of the Scientific Advisory Committee for the Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) and in the ethics committee for the European research infrastructure for Personalised Medicine EATRIS PLUS.
E-mail: Ulrik.Kihlbom@crb.uu.se
Phone: +46 18 471 6233
Teaching
- Medical doctor's programme
- Ethics and public health (7,5 credits, advanced level)
PhD supervision
- Karin Schölin Bywall: The value of patient preferences in drug development for rheumatoid arthritis (main supervisor)
- Ashkan Atry: Is Fair Play Compatible with Doping in Sport?, PhD 2013 (main supervisor)
- Tove Godskesen: Factors associated with participation in phase1 and phase 3 oncology trials, PhD 2015 (main supervisor)
- Elin Inge Lampa: Optimising the involvement of vulnerable populations in health research (co-supervisor)
Recently in the media
- Study explores patient preferences in second-line RA treatment
AJMC, 2021-01-23 - Ansvar bör även läggas på forskningsledaren, Svenska Dagbladet Debatt, 16 March 2016
- Efter skandalen: ”Gråzoner sätt blanda bort korten”, Svenska Dagbladet Debatt, 10 March 2016
Managing genetic risk information
Research generates huge amounts of genetic information. How should we handle it? That is what we are trying to find out in a large international research project.
Patient preferences
Giving patients a voice in drug development
PREFER is a five year public-private research project where academic researchers and the pharmaceutical industry work together to find out when and where patients want, can and should be involved in drug development
Particularism in bioethics
Research network
This network brings together theorists and practitioners from Philosophy, Psychology and Health Care.
Family Ethics
We are part of an international network on ethics of families.
Patient prefrences
Rheumatoid Arthritis
Karin Schölin Bywall will look at how rheumatoid arthritis patient preferences can provide added value in regulatory decision making in the drug development process.
Ethics & law for medical students
Students learn to analyze ethical and legal problems in medical practice and argue for their standpoint.
Public Health Ethics
Learn more about public health ethics! We offer a 7,5 credit course to advanced level students. You need to speak Swedish.
Recent publications
-
Autonomous decisions by couples in reproductive care
Part of BMC Medical Ethics, 2020.
-
Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients
Part of Arthritis Research & Therapy, 2020.
-
How psychological distance of a study sample in discrete choice experiments affects preference measurement: a colorectal cancer screening case study
Part of Patient Preference and Adherence, p. 273-282, 2019.
-
Patient Perspectives on the Value of Patient Preference Information in Regulatory Decision Making: A Qualitative Study in Swedish Patients with Rheumatoid Arthritis
Part of Patient, p. 297-305, 2019.
-
Understanding Patients' Preferences: A Systematic Review of Psychological Instruments Used in Patients' Preference and Decision Studies
Part of Value in Health, p. 491-501, 2019.
Medical ethics, decision-making and patient preferences
Health care and drug development raises several philosophical questions that require practical solutions: How can patients become informed enough to answer questions in a way that is meaningful? How do we make genetic risk information understandable and meaningful? Here, Ulrik Kihlbom reflects on what happens at the intersection of philosophy and empirical work.
